Department of Internal Medicine #3, Bogomolets National Medical University, Kiev, Ukraine.
Medical Clinic, Medical Faculty Mannheim of the University Heidelberg, Mannheim, Germany.
Rheumatol Int. 2022 Dec;42(12):2177-2190. doi: 10.1007/s00296-022-05175-4. Epub 2022 Sep 16.
EULAR highlighted the essential role of digital health in increasing self-management and improving clinical outcomes in patients with arthritis. The objective of this study was to evaluate the efficacy and safety of the digital health application (DHA) in patients with inflammatory arthritis. We assessed demographic parameters, treatment regimen, disease activity, and other patient-reported outcomes at baseline and after 4 weeks of DHA use added to standard care treatment. Of 17 patients, who completed the study, 7 (41.2%) patients were male, ranging from 19 to 63 (40.5 ± 12.2) years. No significant change in antirheumatic treatment was observed during the study. Statistically significant improvements (p < 0.05) were noted for health-related quality of life (increase in Physical Component Summary of Short Form-36 (SF-36) by 23.6%) and disease activity (decrease of Clinical Disease Activity Index and Simple Disease Activity Index by 38.4% and 39.9%, respectively). Clinically significant improvement was demonstrated for SF-36 Total Score (+ 14.4%), disease activity (Rheumatoid Arthritis Disease Activity Index- 5 to 15.9%), and depression (Patient Health Questionnaire- 9 to 13.5%). None of the efficacy parameters showed negative trends. No adverse events were reported throughout the study. The usability level was high i.e., the mean mHealth Application Usability Questionnaire Score of 5.96 (max.: 7.0) demonstrated a high level of application usability. This suggests that using a personalized disease management program based on DHA significantly improves several measures of patient-reported outcomes and disease activity in patients with inflammatory arthritis in a timely manner. These findings highlight the potential of complementary digital therapy in patients with inflammatory arthritis.
EULAR 强调了数字健康在增加关节炎患者自我管理和改善临床结局方面的重要作用。本研究旨在评估炎症性关节炎患者使用数字健康应用程序（DHA）的疗效和安全性。我们在基线时和在标准护理治疗中添加 DHA 使用 4 周后评估了人口统计学参数、治疗方案、疾病活动度和其他患者报告的结果。在完成研究的 17 名患者中，有 7 名（41.2%）为男性，年龄为 19 至 63 岁（40.5±12.2）。在研究期间，抗风湿治疗没有明显变化。健康相关生活质量（SF-36 生理成分综合评分增加 23.6%）和疾病活动度（临床疾病活动指数和简化疾病活动指数分别降低 38.4%和 39.9%）均有显著改善（p<0.05）。SF-36 总分（增加 14.4%）、疾病活动度（类风湿关节炎疾病活动指数 5 至 15.9%）和抑郁（患者健康问卷 9 至 13.5%）均显示出临床显著改善。所有疗效参数均未显示出负面趋势。整个研究过程中均未报告不良事件。可用性水平较高，即平均 mHealth 应用程序可用性问卷评分为 5.96（最高 7.0），表明应用程序具有较高的可用性。这表明，及时使用基于 DHA 的个性化疾病管理方案可显著改善炎症性关节炎患者的多项患者报告结局和疾病活动度。这些发现突显了补充数字疗法在炎症性关节炎患者中的潜在应用价值。
